Sec Form 3 Filing - Ginascol John F @ ABBOTT LABORATORIES - 2019-06-03

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Ginascol John F 2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ ABT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Executive Vice President (Last) (First) (Middle) 100 ABBOTT PARK ROAD 3. Date of Earliest Transaction (MM/DD/YY) 06/03/2019 (Street) ABBOTT PARK, IL60064 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common shares without par value 48,617 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option (right to buy) ( 1 ) $ 47 02/20/2016 02/19/2025 Common shares 57,721 D Option (right to buy) ( 2 ) $ 38.4 02/19/2017 02/18/2026 Common shares 83,333 D Option (right to buy) ( 3 ) $ 44.4 02/17/2018 02/16/2027 Common shares 39,953 D Option (right to buy) ( 4 ) $ 59.94 02/16/2019 02/15/2028 Common shares 38,669 D Option (right to buy) ( 5 ) $ 75.9 02/22/2020 02/21/2029 Common shares 38,190 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Ginascol John F 100 ABBOTT PARK ROAD ABBOTT PARK, IL60064 Executive Vice President Signatures Jessica H. Paik, by power of attorney for John F. Ginascol 06/05/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 19,241 on February 20, 2016, 19,240 on February 20, 2017, and 19,240 on February 20, 2018. ( 2 )Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 27,778 on February 19, 2017, 27,777 on February 19, 2018, and 27,778 on February 19, 2019. ( 3 )Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 13,318 and 13,317 on February 17, 2018 and February 17, 2019, respectively, and an increment of 13,318 becomes exercisable on February 17, 2020. ( 4 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 12,890 on February 16, 2019, and annual increments of 12,889 and 12,890 become exercisable on February 16, 2020 and February 16, 2021, respectively. ( 5 )Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,730 on February 22, 2020, 12,730 on February 22, 2021, and 12,730 on February 22, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.